Washington’s Health Funding Cuts Are A Fatal Mistake—AI Drug Discovery Is About To Transform Healthcare

Posted on by

(SeaPRwire) –   By: Oliver Hawthorne

Washington pulled tens of billions from national health funding. This happens just as healthcare and biotech hit their ChatGPT moment. AI drug discovery leaders say this is the worst possible time to blink.

At Brainstorm Tech in Aspen this week, Lila Sciences CEO Geoffrey von Maltzahn said falling behind on scientific intelligence is an unimaginable competitive disadvantage. NVIDIA’s healthcare VP Kimberly Powell added: if we defund now while Europe and Asia lean in, we’ll be left behind. AI drug discovery is $3.25 billion today, growing 26% annually to $10 billion by 2031. Isomorphic Labs raised $2.1 billion Series B this year. Lila has $550 million for scientific superintelligence—their AI found water-splitting catalysts that outperform precious metals; 1/3 made no sense to Caltech scientists initially.

NVIDIA invests in open-source biology models that companies like Lila use. Closed models would kill innovation. The FDA sign-off issue (untraceable AI data) may be solved with digital twins, but not yet. The end-game? The U.S. will lose its lead in AI drug discovery if it doesn’t reverse funding cuts—letting rivals take over a market that’s set to redefine healthcare.

Author bio: Oliver Hawthorne, Principal Correspondent at an international tech review, covers AI and biotech innovation trends.